TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33332453

Group type: EXPERIMENTAL
Intervention: Optimal paramedic numbers in resuscitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35162126

Group type: EXPERIMENTAL
Intervention: Front-of-package warning labels (WLs) with zero, one, or two labels indicating high sugar, sodium, and/or saturated fats
Number of subjects: 449

Group type: COMPARATOR
Intervention: Unlabeled processed products (Control group)
Number of subjects: 449
Study: 33749069

Group type: EXPERIMENTAL
Intervention: Intervention 1 (two 30-min massages at the effective point of pain for each sole)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intervention 2 (one 30-min massage at the effective point of pain and one 30-min massage at the heel for each sole)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (two 30-minute heel massages)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study: 33127944

Group type: EXPERIMENTAL
Intervention: ANTERION
Number of subjects: 38

Group type: COMPARATOR
Intervention: CASIAII
Number of subjects: 38
Study: 34547260

Group type: EXPERIMENTAL
Intervention: Ticagrelor loading dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous platelet inhibitors
Number of subjects: 0
Study: 33754632

Group type: EXPERIMENTAL
Intervention: Audit and feedback (static or dynamic reports)
Number of subjects: 96185

Group type: COMPARATOR
Intervention: No feedback (control group)
Number of subjects: 96185
Study: 32285747

Group type: EXPERIMENTAL
Intervention: High-threat condition (n = 34)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Low-threat condition (n = 35)
Number of subjects: 69
Study: 36171604

Group type: EXPERIMENTAL
Intervention: People-centered advocacy approach
Number of subjects: 400
Study: 34289935

Group type: EXPERIMENTAL
Intervention: Vitamin D 2,000 IU daily
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 34305816

Group type: EXPERIMENTAL
Intervention: BAT positive group (activated BAT)
Number of subjects: 160
Study: 32880504

Group type: EXPERIMENTAL
Intervention: Virtual reality-based therapy (VRBT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional cardiovascular rehabilitation (CR)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Virtual reality-based therapy (VRBT) after 12 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional cardiovascular rehabilitation (CR) after 12 weeks
Number of subjects: 28
Study: 32075583

Group type: EXPERIMENTAL
Intervention: Aquatic physical intervention (API)
Number of subjects: 42

Group type: COMPARATOR
Intervention: On-land physical intervention (OLPI)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Non-physical intervention (NPI)
Number of subjects: 42
Study: 35198927

Group type: EXPERIMENTAL
Intervention: Individualised nutritional support
Number of subjects: 1389

Group type: COMPARATOR
Intervention: Usual care nutrition
Number of subjects: 1389

Group type: EXPERIMENTAL
Intervention: Low serum albumin group
Number of subjects: 1389
Study: 34579954

Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication review with follow-up
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 0
Study: 32456525

Group type: EXPERIMENTAL
Intervention: Ezetimibe (EZE) + Nutraceutical Compound (NC) containing Monacolin-K, Berberine Hydrochloride, t-Resveratrol, Quercetin, and Chromium (3 months)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Ezetimibe (EZE) in monotherapy (3 months)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Ezetimibe (EZE) + Nutraceutical Compound (NC)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Ezetimibe (EZE) in monotherapy
Number of subjects: 96
Study: 32950246

Group type: EXPERIMENTAL
Intervention: NOL-guided fentanyl dosing
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard care (fentanyl dosing based on haemodynamics)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 50
Study: 35107612

Group type: EXPERIMENTAL
Intervention: Ultramini-percutaneous nephrolithotomy (UMP)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Retrograde intrarenal surgery (RIRS)
Number of subjects: 150
Study: 33894543

Group type: EXPERIMENTAL
Intervention: Nurse-led web-based home asthma education program
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 112
Study: 32513424

Group type: EXPERIMENTAL
Intervention: D-cycloserine
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study: 36316694

Group type: EXPERIMENTAL
Intervention: High ligation of the inferior mesenteric artery (IMA)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Low ligation of the inferior mesenteric artery (IMA)
Number of subjects: 314
Study: 34526307

Group type: EXPERIMENTAL
Intervention: H3 diet (n=61) - increase EPA+DHA to 1.5 g/day and maintain linoleic acid at around 7% of energy
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: H3-L6 diet (n=61) - increase n‐3 EPA+DHA to 1.5 g/day and decrease linoleic acid to ≤1.8% of energy
Number of subjects: 182

Group type: COMPARATOR
Intervention: Control diet (n=60) - maintain EPA+DHA at <150 mg/day and linoleic acid at around 7% of energy
Number of subjects: 182
Study: 32681688

Group type: EXPERIMENTAL
Intervention: Intralesional MMR vaccine
Number of subjects: 74

Group type: COMPARATOR
Intervention: Intralesional vitamin D3
Number of subjects: 74
Study: 34414486

Group type: EXPERIMENTAL
Intervention: Malerba osteotomy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Combined Evans/Medial Displacement Calcaneal Osteotomy (MDCO)
Number of subjects: 34
Study: 34396513

Group type: EXPERIMENTAL
Intervention: PET‐2‐guided escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone)
Number of subjects: 60
Study: 34153451

Group type: EXPERIMENTAL
Intervention: Oblong tablet (2.5 × 6 mm)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Syrup (3 ml glucose syrup)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Mini-tablets (2 × 2 mm)
Number of subjects: 280
Study: 33901109

Group type: EXPERIMENTAL
Intervention: Transplants from donors with infective endocarditis
Number of subjects: 42

Group type: COMPARATOR
Intervention: Matched control transplants
Number of subjects: 42
Study: 34618790

Group type: EXPERIMENTAL
Intervention: Inelastic Lumbosacral Orthoses (iLSOs)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Elastic Lumbosacral Orthoses (eLSOs)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (no LSO)
Number of subjects: 300
Study: 36496367

Group type: EXPERIMENTAL
Intervention: Maxgraft® (freeze‐dried, multiple donors)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Puros® (solvent‐dehydrated, single donor)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (autologous, 10 patients)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group C (patients developing positive LTT at T2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group B (LTT positive T1‐T3)
Number of subjects: 60
Study: 34389407

Group type: EXPERIMENTAL
Intervention: CMT (combined modality therapy) with 20 Gy IF-RT after chemotherapy
Number of subjects: 1150

Group type: COMPARATOR
Intervention: Chemotherapy alone (without IF-RT)
Number of subjects: 1150

Group type: EXPERIMENTAL
Intervention: CMT (combined modality therapy)
Number of subjects: 1150
Study: 32416978

Group type: EXPERIMENTAL
Intervention: HP‐hMG
Number of subjects: 620

Group type: COMPARATOR
Intervention: rFSH
Number of subjects: 620
Study: 34304301

Group type: EXPERIMENTAL
Intervention: Pelargonium sidoides root extracts (n=82)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo (n=82)
Number of subjects: 164
Study: 32551097

Group type: EXPERIMENTAL
Intervention: Nefopam (20 mg doses every 8 hours)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nefopam
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nefopam and Placebo
Number of subjects: 40
Study: 33112417

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 36461035

Group type: EXPERIMENTAL
Intervention: Kami Guibi-tang (KGT)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo granules
Number of subjects: 84
Study: 33550930

Group type: EXPERIMENTAL
Intervention: Psychodynamic-interpersonal psychotherapy (PIT), n=88
Number of subjects: 164

Group type: COMPARATOR
Intervention: Enhanced medical care (EMC), n=76
Number of subjects: 164
Study: 35707180

Group type: EXPERIMENTAL
Intervention: Height ≥170 cm
Number of subjects: 4935

Group type: COMPARATOR
Intervention: Height <160 cm
Number of subjects: 4935
Study: 32065485

Group type: EXPERIMENTAL
Intervention: Chlorhexidine patches (CHG patches)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Standard transparent dressings
Number of subjects: 192
Study: 34100788

Group type: EXPERIMENTAL
Intervention: MHJB training protocol (3 times per week for 6 weeks)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (normal daily workout without MHJB protocol)
Number of subjects: 14
Study: 33361470

Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise (300 minutes per week at 50% to 60% of peak oxygen consumption)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 36316682

Group type: EXPERIMENTAL
Intervention: Culturally adapted lifestyle intervention comprising seven group sessions and a cooking class addressing healthier diet and increased physical activity
Number of subjects: 92

Group type: COMPARATOR
Intervention: Treatment as usual with information to improve lifestyle habits on their own
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Culturally adapted lifestyle intervention
Number of subjects: 92

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 92
Study: 34740351

Group type: EXPERIMENTAL
Intervention: Maternal counselling intervention (five monthly counselling sessions plus usual care)
Number of subjects: 534

Group type: COMPARATOR
Intervention: Usual care alone (control group)
Number of subjects: 534
Study: 35270238

Group type: EXPERIMENTAL
Intervention: Motor skill intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 34551779

Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention (HbA1c ≥ 7%, n = 106)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control group (HbA1c < 7%, n = 95)
Number of subjects: 201
Study: 32958377

Group type: EXPERIMENTAL
Intervention: MOTIFS training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Care‐as‐Usual (CaU) training
Number of subjects: 30
Study: 32493372

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (IM) + Patient-Controlled Epidural Anesthesia (PCEA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intrathecal morphine (IM)
Number of subjects: 50
Study: 34895717

Group type: EXPERIMENTAL
Intervention: Optiflow THRIVE™ at 70 L min‐1 oxygen
Number of subjects: 42

Group type: COMPARATOR
Intervention: Nasal prong oxygen at 4 L min‐1
Number of subjects: 42
Study: 34542058

Group type: EXPERIMENTAL
Intervention: Mézières method (MM)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 54
Study: 32035514

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus pemetrexed-platinum
Number of subjects: 616

Group type: COMPARATOR
Intervention: Placebo plus pemetrexed-platinum
Number of subjects: 616
Study: 35246228

Group type: EXPERIMENTAL
Intervention: EMDR therapy (ten biweekly 90-min sessions)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: EMDR therapy
Number of subjects: 159

Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 159
Study: 34508257

Group type: EXPERIMENTAL
Intervention: Elastic-band resistance training with vitamin D3 supplementation (ED)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Elastic-band resistance training with placebo (EP)
Number of subjects: 40
Study: 33734299

Group type: EXPERIMENTAL
Intervention: Intermediate-dose prophylactic anticoagulation (enoxaparin, 1 mg/kg daily)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Standard-dose prophylactic anticoagulation (enoxaparin, 40 mg daily)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Intermediate-dose prophylactic anticoagulation
Number of subjects: 600

Group type: COMPARATOR
Intervention: Standard-dose prophylactic anticoagulation
Number of subjects: 600
Study: 32061571

Group type: EXPERIMENTAL
Intervention: Mandibular denture with resilient denture liner (RD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mandibular conventional denture (CD)
Number of subjects: 0
Study: 34964363

Group type: EXPERIMENTAL
Intervention: Patient-centered self-management program (once a week for 4 weeks)
Number of subjects: 76
Study: 33569708

Group type: EXPERIMENTAL
Intervention: Shōchū with catechin‐rich green tea (SC)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Shōchū with water (SW)
Number of subjects: 10
Study: 35736193

Group type: EXPERIMENTAL
Intervention: Paternal fish oil diet preconception
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supplemental formula diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Strict maternal milk diet
Number of subjects: 0
Study: 33326064

Group type: EXPERIMENTAL
Intervention: Telmisartan (80 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rosuvastatin/Ezetimibe (20/10 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total Ezetimibe
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ezetimibe
Number of subjects: 0
Study: 34552947

Group type: EXPERIMENTAL
Intervention: Targeted correction of plasma sodium levels
Number of subjects: 2278

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 2278
Study: 32973117

Group type: EXPERIMENTAL
Intervention: SLN biopsy alone
Number of subjects: 600

Group type: COMPARATOR
Intervention: Pelvic lymphadenectomy
Number of subjects: 600
Study: 35102380

Group type: EXPERIMENTAL
Intervention: Severe energy restriction (65%-75% of energy requirement) with total meal replacement diet for 4 months followed by 8 months of moderate energy restriction (25%-35% of energy requirement)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Moderate energy restriction (25%-35% of energy requirement) with a food-based diet for 12 months
Number of subjects: 101
Study: 33820424

Group type: EXPERIMENTAL
Intervention: Supreme Drug-Eluting Stents (DES)
Number of subjects: 1629

Group type: COMPARATOR
Intervention: Durable polymer everolimus-eluting stents (DP-EES)
Number of subjects: 1629

Group type: EXPERIMENTAL
Intervention: Supreme DES
Number of subjects: 1629

Group type: COMPARATOR
Intervention: DP-EES
Number of subjects: 1629
Study: 34449295

Group type: EXPERIMENTAL
Intervention: 274 mg/day ADS-5102
Number of subjects: 558

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: 137 mg/day ADS-5102
Number of subjects: 558
Study: 33663047

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study: 35099997

Group type: EXPERIMENTAL
Intervention: Therapeutic-dose heparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prophylactic-dose heparin
Number of subjects: 0
Study: 33332648

Group type: EXPERIMENTAL
Intervention: Non-cereal hay (lower WSC)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Oaten hay (high WSC)
Number of subjects: 42
Study: 32728819

Group type: EXPERIMENTAL
Intervention: Neurodynamic nerve gliding (ND)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Static stretching (ST)
Number of subjects: 22
Study: 35436859

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Lidocaine 40 mg
Number of subjects: 240

Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 240
Study: 32720916

Group type: EXPERIMENTAL
Intervention: Lottery scratchy ticket reward for good bowel preparation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive education session delivered over the phone by a trained nurse
Number of subjects: 0

Group type: COMPARATOR
Intervention: No additional measure (Control)
Number of subjects: 0
Study: 35265981

Group type: EXPERIMENTAL
Intervention: Non-vitamin K antagonist oral anticoagulant (NOAC)
Number of subjects: 59076

Group type: EXPERIMENTAL
Intervention: Vitamin K antagonist (VKA)
Number of subjects: 59076

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 59076
Study: 36001711

Group type: EXPERIMENTAL
Intervention: Ublituximab (150 mg on day 1, followed by 450 mg on day 15 and at weeks 24, 48, and 72)
Number of subjects: 1094

Group type: EXPERIMENTAL
Intervention: Ublituximab
Number of subjects: 1094

Group type: COMPARATOR
Intervention: Teriflunomide (14 mg once daily)
Number of subjects: 1094

Group type: COMPARATOR
Intervention: Teriflunomide
Number of subjects: 1094
Study: 34155687

Group type: EXPERIMENTAL
Intervention: Simulation-based education programme including five online-learning delirium care videos, one face-to-face education session, and a role-play scenario-based initiative.
Number of subjects: 72

Group type: COMPARATOR
Intervention: Online videos (same as provided to the intervention group).
Number of subjects: 72
Study: 32897129

Group type: EXPERIMENTAL
Intervention: Circumcised partners
Number of subjects: 4982

Group type: COMPARATOR
Intervention: Uncircumcised partners
Number of subjects: 4982
Study: 34837305

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate mouthwash (15 ml for 1 min)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate mouthwash
Number of subjects: 100
Study: 34806471

Group type: EXPERIMENTAL
Intervention: Near-infrared fluorescent cholangiography (NIFC) with indocyanine green (ICG)
Number of subjects: 161

Group type: COMPARATOR
Intervention: White light imaging (control group)
Number of subjects: 161
Study: 35433276

Group type: EXPERIMENTAL
Intervention: Online group psychoeducation sessions
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Online progressive muscle relaxation (PMR) group sessions
Number of subjects: 69

Group type: COMPARATOR
Intervention: No group sessions (control condition)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: All conditions (including control)
Number of subjects: 69
Study: 33755640

Group type: EXPERIMENTAL
Intervention: Ethyl chloride topical anesthetic spray
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (tissue culture grade water)
Number of subjects: 100
Study: 32787943

Group type: EXPERIMENTAL
Intervention: Feel4Diabetes intervention (family, school, and community components, including 6 counseling sessions for families at risk)
Number of subjects: 898

Group type: EXPERIMENTAL
Intervention: Feel4Diabetes intervention
Number of subjects: 898
Study: 34882827

Group type: EXPERIMENTAL
Intervention: Machine learning-based ultrasomic analysis
Number of subjects: 324
Study: 35168907

Group type: EXPERIMENTAL
Intervention: Volatile anesthetics (desflurane, isoflurane, or sevoflurane)
Number of subjects: 5400
Study: 34603073

Group type: EXPERIMENTAL
Intervention: Moderate Continuous Training (MCT)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control
Number of subjects: 62
Study: 34574438

Group type: EXPERIMENTAL
Intervention: Trained volunteer-led community-based intervention
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 21
Study: 32471369

Group type: EXPERIMENTAL
Intervention: Digital insertion of Foley catheter
Number of subjects: 86

Group type: COMPARATOR
Intervention: Speculum insertion of Foley catheter
Number of subjects: 86
Study: 36007724

Group type: EXPERIMENTAL
Intervention: CTgRT (Stereotactic Body Radiation Therapy with CT guidance)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MRgRT (Stereotactic Body Radiation Therapy with MRI guidance)
Number of subjects: 100
Study: 33526485

Group type: EXPERIMENTAL
Intervention: Rectal artesunate (10 mg/kg) followed by intravenous artesunate (2.4 mg/kg)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Intravenous artesunate (2.4 mg/kg)
Number of subjects: 82
Study: 32327428

Group type: EXPERIMENTAL
Intervention: TNF inhibition (TNFi)
Number of subjects: 2420
Study: 35317614

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg once daily for 7 days
Number of subjects: 382

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382
Study: 32875733

Group type: EXPERIMENTAL
Intervention: Ketogenic diet without any restriction on energy intake
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Commercial energy‐restricted ketogenic Mediterranean diet
Number of subjects: 50

Group type: COMPARATOR
Intervention: Energy‐restricted Mediterranean diet
Number of subjects: 50
Study: 36942060

Group type: EXPERIMENTAL
Intervention: Melatonin 6 mg daily for four weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 32640882

Group type: EXPERIMENTAL
Intervention: Serial 12-lead electrocardiograms once daily for five days
Number of subjects: 826

Group type: COMPARATOR
Intervention: 24‐h Holter monitoring
Number of subjects: 826
Study: 33491027

Group type: EXPERIMENTAL
Intervention: Multicomponent exercise program (VIVIFRAIL) for 12 weeks, minimum 3 weekly sessions of 45–60 minutes
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group received physical daily training (yoga, cardio-dance or tai chi)
Number of subjects: 61
Study: 32093882

Group type: EXPERIMENTAL
Intervention: Underbleb subtenonian anesthesia (USA)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Peribulbar anesthesia (PA)
Number of subjects: 97
Study: 32930513

Group type: EXPERIMENTAL
Intervention: Current mental ill-health risk profile (n = 119)
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Achievable mental ill-health risk profile (n = 118)
Number of subjects: 355

Group type: COMPARATOR
Intervention: Control group (n = 118)
Number of subjects: 355